Patterns of Uptake, Engagement, and Attrition in Randomized Controlled Trials of Digital Interventions for Eating Disorders: A Systematic Review and Meta-Analysis
Abstract
Objective: This review aimed to quantify rates of uptake (treatment initiation), adherence (program completion), and attrition (study dropout) in randomized trials of digital eating disorder (ED) interventions, and to synthesize engagement reporting practices, their consistency, and associations with clinical outcomes.
Methods: Randomized trials of digital interventions (web, app, computerized, chatbots, etc.) delivered to people with diagnostic, subthreshold, or self-reported EDs were included. Random-effects meta-analyses were conducted to compute absolute rates of uptake, adherence, and attrition, while a narrative synthesis summarized engagement patterns and reporting.
Results: Forty-eight trials were included. The weighted mean uptake rate from 44 intervention conditions was 89.7% (95% PI = 67.0-97.0) and the weighted mean adherence rate from 14 intervention conditions was 41.8% (95% PI = 0.9-83.3). These estimates remained similar in a series of sensitivity analyses that adjusted for biases, outliers, and when limiting to specific clinical population groups. The weighted trial attrition rate was 23.3% (95% PI = 0.8-54.4); for intervention arms specificially it was 29.7% (95% PI = 9.7-62.3) and for waitlist arms it was 18.7% (95% PI = 4.6-52.3). Attrition was lower in trials that had human-participant interaction, offered therapeutic guidance, provided monetary reimbursement, tested a web/computer program (compared to a smartphone application), and had a longer…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.